Calidi Biotherapeutics Closes $3.9 Million in Funding
In a notable advancement for its innovative immunotherapy solutions, Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a company at the forefront of clinical-stage biotechnology, has announced the successful closing of a substantial funding round. The company completed a registered direct offering with an institutional investor, securing the issuance of 3,325,000 shares of common stock along with pre-funded warrants to purchase an additional 2,728,000 shares of common stock.
Details of the Offering
This funding round, which also included a concurrent private placement, has raised approximately $3.9 million before expenses. The terms of the offering specified a combined price of $0.65 per share of common stock or $0.649 for the pre-funded warrants. The latter come with an exercise price set at an extremely favorable $0.001 per share, allowing for immediate exercise upon issuance without an expiration period until fully exercised.
Strategic Goals for the Raised Funds
The net proceeds from these offerings are designated for working capital and other essential corporate purposes, including the enhancement of Calidi's clinical and pre-clinical development programs. This strategic funding is expected to propel the company further into its mission of revolutionizing cancer treatment through advanced immunotherapies.
The Role of Placement Agents
Serving as the exclusive placement agent for this offering was Ladenburg Thalmann & Co. Inc. Their expertise played a crucial role in enabling Calidi to successfully navigate this financial endeavor, culminating in the closing on March 31, 2025.
Understanding Calidi's Innovations
Calidi Biotherapeutics is recognized for its pioneering work within the immuno-oncology sector, leveraging proprietary technology that empowers the immune system in the fight against cancer. The company employs advanced, stem cell-based platforms designed to transport powerful oncolytic viruses, targeting a range of oncology indications, including hard-to-treat solid tumors and high-grade gliomas.
Unique Approach in Cancer Treatment
Calidi’s clinical-stage products aim to enhance the efficacy of virotherapies while improving patient safety, showcasing a commitment to comprehensive cancer treatment solutions. Their innovative approach includes off-the-shelf, universal cell-based delivery systems engineered to amplify oncolytic viral effects against solid tumors, potentially preventing metastasis.
Looking Ahead
Calidi’s strategy underscores its dedication to innovation within cancer research and treatment realms. By securing these funds, the company is well-positioned to advance its groundbreaking initiatives in the biotherapeutic landscape, harnessing state-of-the-art technology to develop dynamic therapies for patients.
Contact Information for Inquiries
For further insights or inquiries regarding this announcement, interested parties can reach out to Dave Gentry, CEO of RedChip Companies, at 1-407-644-4256 or contact via email at CLDI@redchip.com. Your engagement is highly valued as Calidi continues to push boundaries in cancer therapy.
Frequently Asked Questions
What is the amount raised by Calidi Biotherapeutics?
Calidi Biotherapeutics successfully closed a funding round raising approximately $3.9 million.
What types of securities were issued in this offering?
The offering included common stock shares and pre-funded warrants, along with Series G common warrants.
What are the intended uses for the proceeds from the offering?
The net proceeds will be allocated to working capital, corporate purposes, and advancing clinical programs.
Who acted as placement agent for the offerings?
Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the funding round.
What is Calidi Biotherapeutics known for?
Calidi Biotherapeutics is known for its innovative immunotherapy solutions and advanced technologies aimed at fighting various cancers.
